Found: 5
Select item for more details and to access through your institution.
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 11, p. 1, doi. 10.1093/ofid/ofad526
- By:
- Publication type:
- Article
Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 5, p. 1127, doi. 10.1007/s40121-024-00965-8
- By:
- Publication type:
- Article
Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 8, p. 2039, doi. 10.1007/s40121-023-00840-y
- By:
- Publication type:
- Article
Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 3, p. 389, doi. 10.1002/ejhf.2788
- By:
- Publication type:
- Article
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study.
- Published in:
- PharmacoEconomics, 2024, v. 42, n. 3, p. 329, doi. 10.1007/s40273-023-01337-9
- By:
- Publication type:
- Article